Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA

Brahe C. H., Ornbjerg L. M., Jacobsson L., Nissen M. J., Kristianslund E. K., Mann H., ...Daha Fazla

RHEUMATOLOGY, cilt.59, sa.7, ss.1640-1650, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 59 Sayı: 7
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1093/rheumatology/kez427
  • Dergi Adı: RHEUMATOLOGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, BIOSIS, CINAHL, EMBASE, International Pharmaceutical Abstracts, MEDLINE
  • Sayfa Sayıları: ss.1640-1650
  • Anahtar Kelimeler: psoriatic arthritis, spondyloarthritis, TNFi, effectiveness, drug survival, response, epidemiology, register, DAS28, DAPSA28, NECROSIS-FACTOR INHIBITORS, MODIFYING ANTIRHEUMATIC DRUGS, PSORIATIC-ARTHRITIS, RHEUMATOID-ARTHRITIS, PREDICTORS THEREOF, CLINICAL-PRACTICE, INFLIXIMAB, SURVIVAL, THERAPY, COMEDICATION
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

Objective. To investigate TNF inhibitor (TNFi) retention and response rates in European biologic-naive patients with PsA.